Captrust Financial Advisors Trims Stock Position in Johnson & Johnson (NYSE:JNJ)

Captrust Financial Advisors decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 533,600 shares of the company's stock after selling 5,127 shares during the quarter. Captrust Financial Advisors' holdings in Johnson & Johnson were worth $77,169,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of JNJ. IFS Advisors LLC grew its holdings in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after buying an additional 100 shares in the last quarter. WealthTrak Capital Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson during the fourth quarter valued at about $29,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $32,000. Finally, Conquis Financial LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.3 %

Shares of NYSE:JNJ traded down $0.40 during trading on Tuesday, hitting $154.60. The company had a trading volume of 8,634,326 shares, compared to its average volume of 7,890,010. The stock has a market cap of $371.97 billion, a price-to-earnings ratio of 23.25, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a fifty day simple moving average of $158.51 and a two-hundred day simple moving average of $154.47. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.36%. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent analyst reports. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Wells Fargo & Company reduced their price target on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Barclays cut their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Finally, The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $171.82.

Insider Activity

In related news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.